Literature DB >> 4118761

A second international cooperative investigation into tioacetazone side effects.

A B Miller, A J Nunn, D K Robinson, W Fox, P R Somasundaram, R Tall.   

Abstract

As part of a large-scale international cooperative investigation into the side effects of thioacetazone-containing regimens in the treatment of tuberculosis, an evaluation has been made of the variation in the frequency of side effects between different countries and between different centres in the same country and of the likely reasons for this variation. In 3 countries patients of different racial origin were under observation in the same hospital. Over a 12-week period of treatment there was considerable variation between the countries and centres in the overall frequency of side effects and of those leading to a major departure from prescribed treatment, the variation being similar for the two thioacetazone-containing regimens and for the streptomycin plus isoniazid control regimen, though at a lower level for the latter. In Malaysia, Singapore, and Trinidad, where different racial groups were under treatment, there was no clear indication that race was an important factor in explaining the differences between countries, except for cutaneous side effects in Trinidad and possibly in Malaysia.It is concluded that the differences in the frequency of side effects to thioacetazone-containing regimens probably result from variation in the closeness of supervision of patients, in the recording and interpretation of side effects, and in environmental factors including the previous use of other medicaments or exposure to sensitizing substances.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4118761      PMCID: PMC2480900     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  A second international co-operative investigation into thiacetazone side-effects. Rashes on two thiacetazone containing regimens.

Authors:  G C Ferguson; A J Nunn; W Fox; A B Miller; D K Robinson; R Tall
Journal:  Tubercle       Date:  1971-09

2.  Haemolytic anaemia in a patient taking thioacetazone.

Authors:  M A Masel; N G Johnston
Journal:  Med J Aust       Date:  1968-11-09       Impact factor: 7.738

3.  [Comparative study of 2 types of oral therapy of pulmonary tuberculosis (ethionamide and isoniazid, thiacetazone and isoniazid)].

Authors:  F J Chicou; G Hétrick; M Huet; H Radenac; N Rist
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

Review 4.  The role of migrant population in studies of selected cancer sites: a review.

Authors:  J Kmet
Journal:  J Chronic Dis       Date:  1970-11

5.  Differenital mortality from cardiovascular disease in migrants from England and Wales, Scotland and Italy, and native-born Australians.

Authors:  N S Stenhouse; M G McCall
Journal:  J Chronic Dis       Date:  1970-11

6.  Opportunities for studies of cardio-respiratory diseases in migrants.

Authors:  A Kagan
Journal:  J Chronic Dis       Date:  1970-11
  6 in total
  5 in total

1.  Adverse effects of antituberculosis drugs.

Authors:  D J Girling
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

Review 2.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 3.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

4.  Pharmacovigilance and tuberculosis: applying the lessons of thioacetazone.

Authors:  Dennis Falzon; Geraldine Hill; Shanthi N Pal; Wimon Suwankesawong; Ernesto Jaramillo
Journal:  Bull World Health Organ       Date:  2014-10-07       Impact factor: 9.408

5.  Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach.

Authors:  Grace Mugumbate; Vitor Mendes; Michal Blaszczyk; Mohamad Sabbah; George Papadatos; Joel Lelievre; Lluis Ballell; David Barros; Chris Abell; Tom L Blundell; John P Overington
Journal:  Front Pharmacol       Date:  2017-09-26       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.